^
ATRX mutation
Uterine Corpus Leiomyosarcoma
BAY 1895344
Sensitive
:
D
IGCS 2022 - 2 weeks - (New D)
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive
:
A2
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AZD5363
Sensitive
:
C3
CD70 expression
Uterine Corpus Leiomyosarcoma
ARX305
Sensitive
:
C3
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive
:
C3
PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive
:
C3
ER positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive
:
C3
PALB2 deletion
Uterine Corpus Leiomyosarcoma
olaparib
Sensitive
:
C3
RAD51B deletion
Uterine Corpus Leiomyosarcoma
olaparib
Sensitive
:
C3
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
lorlatinib
Sensitive
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
alectinib
Sensitive
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
crizotinib
Resistant
:
C4
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
pazopanib
Resistant
:
C4
BRCA2 mutation
Uterine Corpus Leiomyosarcoma
PARP inhibitor
Sensitive
:
D